**Federal marijuana policy has advanced in phases under the Trump administration.** In April 2026, Acting Attorney General Todd Blanche issued a final order immediately moving FDA-approved marijuana products and state-licensed medical marijuana to Schedule III of the Controlled Substances Act, providing Section 280E tax relief for qualifying medical operators while adult-use cannabis remained Schedule I. An expedited DEA administrative hearing on broader rescheduling, including recreational marijuana, ran from June 29 to July 15, 2026, before ALJ Derek C. Julius. The DEA’s post-hearing brief strongly supported moving all botanical marijuana to Schedule III, citing HHS/FDA findings of accepted medical use. Opposing participants emphasized abuse potential and youth exposure. On September 9, 2026, the D.C. Circuit rejected efforts to stay the April order. The ALJ’s recommendation and any final rule now shape the timeline for full rescheduling.
Ringkasan eksperimental yang dihasilkan AI dengan referensi data Polymarket. Ini bukan saran trading dan tidak berperan dalam bagaimana pasar ini diselesaikan. · Diperbarui$809,982 Vol.
September 30
2%
December 31
15%
$809,982 Vol.
September 30
2%
December 31
15%
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Pasar Dibuka: Jul 31, 2026, 5:46 PM ET
Resolver
0x65070BE91...The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Resolver
0x65070BE91...**Federal marijuana policy has advanced in phases under the Trump administration.** In April 2026, Acting Attorney General Todd Blanche issued a final order immediately moving FDA-approved marijuana products and state-licensed medical marijuana to Schedule III of the Controlled Substances Act, providing Section 280E tax relief for qualifying medical operators while adult-use cannabis remained Schedule I. An expedited DEA administrative hearing on broader rescheduling, including recreational marijuana, ran from June 29 to July 15, 2026, before ALJ Derek C. Julius. The DEA’s post-hearing brief strongly supported moving all botanical marijuana to Schedule III, citing HHS/FDA findings of accepted medical use. Opposing participants emphasized abuse potential and youth exposure. On September 9, 2026, the D.C. Circuit rejected efforts to stay the April order. The ALJ’s recommendation and any final rule now shape the timeline for full rescheduling.
Ringkasan eksperimental yang dihasilkan AI dengan referensi data Polymarket. Ini bukan saran trading dan tidak berperan dalam bagaimana pasar ini diselesaikan. · Diperbarui



Hati-hati dengan link eksternal.
Hati-hati dengan link eksternal.
Pertanyaan yang Sering Diajukan